Cargando…

Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen

High-throughput phenotypic screens have re-emerged as screening tools in antibiotic discovery. The advent of such technologies has rapidly accelerated the identification of ‘hit’ compounds. A pre-requisite to medicinal chemistry optimisation programmes required to improve the drug-like properties of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cox, Jonathan A. G., Mugumbate, Grace, Del Peral, Laura Vela-Glez, Jankute, Monika, Abrahams, Katherine A., Jervis, Peter, Jackenkroll, Stefan, Perez, Arancha, Alemparte, Carlos, Esquivias, Jorge, Lelièvre, Joël, Ramon, Fernando, Barros, David, Ballell, Lluis, Besra, Gurdyal S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159837/
https://www.ncbi.nlm.nih.gov/pubmed/27982051
http://dx.doi.org/10.1038/srep38986
_version_ 1782481829908971520
author Cox, Jonathan A. G.
Mugumbate, Grace
Del Peral, Laura Vela-Glez
Jankute, Monika
Abrahams, Katherine A.
Jervis, Peter
Jackenkroll, Stefan
Perez, Arancha
Alemparte, Carlos
Esquivias, Jorge
Lelièvre, Joël
Ramon, Fernando
Barros, David
Ballell, Lluis
Besra, Gurdyal S.
author_facet Cox, Jonathan A. G.
Mugumbate, Grace
Del Peral, Laura Vela-Glez
Jankute, Monika
Abrahams, Katherine A.
Jervis, Peter
Jackenkroll, Stefan
Perez, Arancha
Alemparte, Carlos
Esquivias, Jorge
Lelièvre, Joël
Ramon, Fernando
Barros, David
Ballell, Lluis
Besra, Gurdyal S.
author_sort Cox, Jonathan A. G.
collection PubMed
description High-throughput phenotypic screens have re-emerged as screening tools in antibiotic discovery. The advent of such technologies has rapidly accelerated the identification of ‘hit’ compounds. A pre-requisite to medicinal chemistry optimisation programmes required to improve the drug-like properties of a ‘hit’ molecule is identification of its mode of action. Herein, we have combined phenotypic screening with a biased target-specific screen. The inosine monophosphate dehydrogenase (IMPDH) protein GuaB2 has been identified as a drugable target in Mycobacterium tuberculosis, however previously identified compounds lack the desired characteristics necessary for further development into lead-like molecules. This study has identified 7 new chemical series from a high-throughput resistance-based phenotypic screen using Mycobacterium bovis BCG over-expressing GuaB2. Hit compounds were identified in a single shot high-throughput screen, validated by dose response and subjected to further biochemical analysis. The compounds were also assessed using molecular docking experiments, providing a platform for their further optimisation using medicinal chemistry. This work demonstrates the versatility and potential of GuaB2 as an anti-tubercular drug target.
format Online
Article
Text
id pubmed-5159837
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51598372016-12-21 Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen Cox, Jonathan A. G. Mugumbate, Grace Del Peral, Laura Vela-Glez Jankute, Monika Abrahams, Katherine A. Jervis, Peter Jackenkroll, Stefan Perez, Arancha Alemparte, Carlos Esquivias, Jorge Lelièvre, Joël Ramon, Fernando Barros, David Ballell, Lluis Besra, Gurdyal S. Sci Rep Article High-throughput phenotypic screens have re-emerged as screening tools in antibiotic discovery. The advent of such technologies has rapidly accelerated the identification of ‘hit’ compounds. A pre-requisite to medicinal chemistry optimisation programmes required to improve the drug-like properties of a ‘hit’ molecule is identification of its mode of action. Herein, we have combined phenotypic screening with a biased target-specific screen. The inosine monophosphate dehydrogenase (IMPDH) protein GuaB2 has been identified as a drugable target in Mycobacterium tuberculosis, however previously identified compounds lack the desired characteristics necessary for further development into lead-like molecules. This study has identified 7 new chemical series from a high-throughput resistance-based phenotypic screen using Mycobacterium bovis BCG over-expressing GuaB2. Hit compounds were identified in a single shot high-throughput screen, validated by dose response and subjected to further biochemical analysis. The compounds were also assessed using molecular docking experiments, providing a platform for their further optimisation using medicinal chemistry. This work demonstrates the versatility and potential of GuaB2 as an anti-tubercular drug target. Nature Publishing Group 2016-12-16 /pmc/articles/PMC5159837/ /pubmed/27982051 http://dx.doi.org/10.1038/srep38986 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Cox, Jonathan A. G.
Mugumbate, Grace
Del Peral, Laura Vela-Glez
Jankute, Monika
Abrahams, Katherine A.
Jervis, Peter
Jackenkroll, Stefan
Perez, Arancha
Alemparte, Carlos
Esquivias, Jorge
Lelièvre, Joël
Ramon, Fernando
Barros, David
Ballell, Lluis
Besra, Gurdyal S.
Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen
title Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen
title_full Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen
title_fullStr Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen
title_full_unstemmed Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen
title_short Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen
title_sort novel inhibitors of mycobacterium tuberculosis guab2 identified by a target based high-throughput phenotypic screen
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159837/
https://www.ncbi.nlm.nih.gov/pubmed/27982051
http://dx.doi.org/10.1038/srep38986
work_keys_str_mv AT coxjonathanag novelinhibitorsofmycobacteriumtuberculosisguab2identifiedbyatargetbasedhighthroughputphenotypicscreen
AT mugumbategrace novelinhibitorsofmycobacteriumtuberculosisguab2identifiedbyatargetbasedhighthroughputphenotypicscreen
AT delperallauravelaglez novelinhibitorsofmycobacteriumtuberculosisguab2identifiedbyatargetbasedhighthroughputphenotypicscreen
AT jankutemonika novelinhibitorsofmycobacteriumtuberculosisguab2identifiedbyatargetbasedhighthroughputphenotypicscreen
AT abrahamskatherinea novelinhibitorsofmycobacteriumtuberculosisguab2identifiedbyatargetbasedhighthroughputphenotypicscreen
AT jervispeter novelinhibitorsofmycobacteriumtuberculosisguab2identifiedbyatargetbasedhighthroughputphenotypicscreen
AT jackenkrollstefan novelinhibitorsofmycobacteriumtuberculosisguab2identifiedbyatargetbasedhighthroughputphenotypicscreen
AT perezarancha novelinhibitorsofmycobacteriumtuberculosisguab2identifiedbyatargetbasedhighthroughputphenotypicscreen
AT alempartecarlos novelinhibitorsofmycobacteriumtuberculosisguab2identifiedbyatargetbasedhighthroughputphenotypicscreen
AT esquiviasjorge novelinhibitorsofmycobacteriumtuberculosisguab2identifiedbyatargetbasedhighthroughputphenotypicscreen
AT lelievrejoel novelinhibitorsofmycobacteriumtuberculosisguab2identifiedbyatargetbasedhighthroughputphenotypicscreen
AT ramonfernando novelinhibitorsofmycobacteriumtuberculosisguab2identifiedbyatargetbasedhighthroughputphenotypicscreen
AT barrosdavid novelinhibitorsofmycobacteriumtuberculosisguab2identifiedbyatargetbasedhighthroughputphenotypicscreen
AT ballelllluis novelinhibitorsofmycobacteriumtuberculosisguab2identifiedbyatargetbasedhighthroughputphenotypicscreen
AT besragurdyals novelinhibitorsofmycobacteriumtuberculosisguab2identifiedbyatargetbasedhighthroughputphenotypicscreen